Close Menu

GSK

This story originally ran on Sept. 14.

Enigma Diagnostics and GlaxoSmithKline said today that they have signed a supply and commercialization agreement for molecular diagnostic tests for use on Engima's fully automated, sample-to-answer real-time PCR system, breathing new life into a partnership begun in 2009.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.

Participating vendors are being asked to build fully functional platforms for next-generation sequence data storage and analysis.

The discovery triggered a milestone payment of an undisclosed amount, Regulus said.

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

The company claims Agilent, 454 Life Sciences, Navigenics, Pfizer, and others are infringing on its patent covering a method for analyzing non-coding DNA sequences.

Efforts spearheaded by Sage Bionetworks and Genetic Alliance hope to encourage drug developers to share precompetitive genomic data from the comparator arms of drug trials and to give study participants more control over their own data generated in clinical investigations.

Pages

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.